Efficacy and Safety of Hydromorphone or Sufentanil Combined With Programmed Epidural Intermittent Administration of Ropivacaine for Labor Analgesia ---- a Randomized, Controlled, Double-blind, Non-inferiority Study - Efficacy and Safety of Hydromorphone or Sufentanil Combined With Programmed Epidural Intermittent Administration of Ropivacaine for Labor Analgesia ---- a Randomized, Controlled, Double-blind, Non-inferiority Study

Start Date01 Sep 2025

Sponsor / Collaborator-

ChiCTR2500098772

/ SuspendedPhase 4IIT

Comparison of efficacy and safety of Afentanil, oxelidine fumarate, Sufentanil combined with etomidate and propofol in painless gastroscopy

Start Date15 Apr 2025

Sponsor / Collaborator-

NCT06917651

/ Not yet recruitingPhase 3IIT

Management of Moderate to Severe Monotraumatic Pain With Sublingual Sufentanil in an Emergency Situation.

Pain is a common reason for emergency department (ED) visits. However, studies suggest that emergency physicians may not always provide optimal analgesic treatment due to various factors, such as time constraints, demographic factors like gender and age, and concerns about opioid use. As a result, patients with moderate to severe pain often experience long delays before receiving analgesia and may even be discharged with unresolved pain or suboptimal treatment. Additionally, diagnostic procedures for patients with isolated trauma (e.g., clinical examinations, radiographs) can lead to variations in pain levels, making it difficult to assess the effectiveness of analgesia.
A commonly used treatment for moderate to severe pain is intravenous opioid administration. However, this approach requires longer wait times, complex titration, and significant resources (beds, nurses, equipment), which may be limited during peak hours. While oral opioids require fewer resources, their delayed onset and limited titratability restrict their use for severe pain.
The sublingual sufentanil tablet (30 mcg), delivered via a single-dose applicator, was developed for patients with moderate to severe pain in emergency or outpatient surgical settings. Its unique pharmacokinetic and pharmacodynamic properties could offer advantages in non-invasive acute pain management.
Sublingual sufentanil received market authorization in June 2018 for the treatment of moderate to severe acute pain in adults and is already used in many hospitals. However, further studies are needed to confirm its effectiveness and potential superiority in pain management.
The objective of this study is to evaluate the effectiveness of 30 mcg sublingual sufentanil in patients admitted for moderate to severe pain due to isolated trauma. This will be compared to the standard pain management protocol used in the Clermont-Ferrand emergency department, focusing on pain score variations using a numerical rating scale (0-10)

Start Date02 Apr 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire de Clermont Ferrand

100 Clinical Results associated with Sufentanil Citrate

100 Translational Medicine associated with Sufentanil Citrate

100 Patents (Medical) associated with Sufentanil Citrate

3,829

Literatures (Medical) associated with Sufentanil Citrate

01 Jun 2025·FOOD CHEMISTRY

High-throughput screening of new psychoactive substances and related compounds in food by UHPLC-Q/Orbitrap

Article

Author: Huang, Xia ; Wan, Yuping ; Shi, Peiyu ; Wu, Wenlin ; Xiao, Quanwei ; Liu, Shiyao ; Guo, Tianrong ; Zhang, Min ; Xia, Bing ; Zhou, Yan ; Chen, Xiaoqi

Currently, there is concern about food products to which new psychoactive substances (NPS) have been added illegally. However, rapid, high-sensitivity, and high-throughput screening methods for such harmful substances have not been reported yet. In this study, a high-throughput non-targeted screening strategy was developed based on UHPLC-Q/Orbitrap. First, optimized pretreatment methods for typical high-risk matrices were established. Second, an accurate, efficient, and scalable high resolution mass spectrometry database containing 206 NPS and related compounds was constructed. The fragmentation pathways of three different types of fentanyl-related compounds were then systematically investigated to enhance compound identification. Additionally, a non-targeted screening strategy was developed using warning ions derived from 24 fentanyl-related compounds, streamlining the identification of NPS. This strategy was applied to 100 food samples with possible illegal additives and demonstrated its effectiveness. In summary, this study provides robust technical support for regulatory authorities in combating the illegal addition of food products.

01 Jun 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A chemoinformatics study to prioritization of anticancer orally active lead compounds of pearl millet against adhesion G protein-coupled receptor

Article

Author: Shukla, Adarsh Kumar ; Neeru ; Kumar, Ashwani

Metastasis is the main cause of colon cancer deaths worldwide. However, due to the disease's complexity, understanding its spread and finding natural treatments remain major challenges. The study aimed to identify therapeutic compounds in pearl millet and test them on metastatic colon cancer cell lines. The study used LC-MS and FTIR spectroscopy to identify small compounds and their functional groups. Further, theoretical chemistry, computational techniques, and ADMET analysis were applied for virtual screening and evaluating the pharmacokinetics of potential bioactive candidates of pearl millet. The 55 compounds of pearl millet were identified through the LC-MS, whereas 37 compounds were reported in PubChem database. Out of these, 15 compounds were predicted as potential orally active leads of pearl millet. Adhesion G protein-coupled receptor F5 was found as a potential target of these lead candidates. Further, molecular docking exhibited Tosifen (-7.9 kcal/mol), Sufentanil (-6.4 kcal/mol), Pemirolast (-6.3 kcal/mol), and Levosimendan (-6.3 kcal/mol) have similar binding affinity to the antineoplastics against the targeted protein. The "root mean square fluctuations (RMSFs)" analysis and deformability graph validated the docked complexes. Additionally, a comparative cell lines study against colon adenocarcinoma highlights Pemirolast as a promising candidate, demonstrating better activity compared to standard antineoplastics. This computational study predicted potential anticancer compounds in pearl millet and recommended further investigation through in vitro and in vivo studies.

01 Mar 2025·Molecular biotechnology

Sufentanil Suppresses Cell Carcinogenesis Via Targeting miR-186-5p/HMGB1 Axis and Wnt/β-Catenin Pathway in Non-Small-Cell Lung Cancer

Article

Author: Shang, You ; Huang, Ye ; Liu, Di

Sufentanil is a common opioid anesthetic agent, which exerts anti-cancer properties in several cancer types. However, its action mechanisms in non-small cell lung cancer (NSCLC) are unclear. Therefore, the present study investigated the pharmacological effect of sufentanil on miRNAs in NSCLC treatment. In this study, after treatment with sufentanil, the proliferation, migration, invasion and apoptosis of A549 and H1299 NSCLC cell lines were measured by cell counting kit-8 (CCK-8) assay, colony formation assay, transwell assays and flow cytometry. Quantitative real time polymerase chain reaction (qRT-PCR) was utilized to detect the expression of miR-186-5p and high mobility group box-1 (HMGB1), and their interaction was analyzed using luciferase reporter assay. The proteins of HMGB1, and apoptosis- and Wnt/β-catenin pathway-related factors were detected by western blot. It was demonstrated that sufentanil significantly upregulated miR‑186‑5p to restrict NSCLC cell proliferation, migration, invasion, and boost apoptosis in vitro. Mechanically, miR-186-5p interacted with HMGB1 and negatively regulated HMGB1 in NSCLC cells. Furthermore, rescue assay showed that sufentanil exerted antitumor activities by upregulating miR-186-5p, which targeted HMGB1 and restrained Wnt/β-catenin signal pathway in NSCLC cells. In conclusion, these results suggested that sufentanil disrupts the oncogenicity of NSCLC cells by regulating miR-186-5p/HMGB1/β-catenin axis, providing a promising implication for the anti-oncogenic effect of sufentanil.

News (Medical) associated with Sufentanil Citrate

14 Apr 2025

·www.globenewswire.com

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related upfront, milestone, and royalty payments paid to XOMA Royalty prior to April 2, 2029 EMERYVILLE, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has completed the sale of all five pipeline assets that were acquired when XOMA Royalty closed its acquisition of Kinnate Biopharma Inc. on April 3, 2024. Pursuant to the terms of the related asset purchase agreements, XOMA Royalty is entitled to upfront and milestone payments of up to $270 million and future royalty payments at rates ranging from the low single digits to mid-teens on commercial sales tied to these assets. “In addition to distributing the majority of Kinnate’s cash balance to its existing shareholders upon closing of the acquisition, we have also created the potential for additional upside by selling all of Kinnate’s early-stage pipeline products,” stated Owen Hughes, Chief Executive Officer of XOMA Royalty. “Per the terms of the Kinnate acquisition agreement, legacy Kinnate shareholders will receive, by way of their Kinnate Contingent Value Rights (CVRs), 85% of payments received by XOMA Royalty prior to April 2, 2029, including all related upfront, milestones, and royalty payments, related to these Kinnate assets.” About XOMA Royalty CorporationXOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn. Forward-Looking Statements/Explanatory NotesCertain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential upfront, milestone, and royalty payments to XOMA Royalty, the ensuing payments to legacy Kinnate shareholders by way of their Kinnate Contingent Value Rights, and other developments related to the Kinnate assets. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will”, “would,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA Royalty’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that the Kinnate pipeline assets for which we have milestone and royalty interests are still being developed, and the purchasers of these assets may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for these products; and if these products do not receive regulatory approval, the purchasers of these assets will not be able to market them. Other potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA Royalty's prospects. Any forward-looking statement in this press release represents XOMA Royalty's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by applicable law. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. Investor contact:Media contact:Juliane SnowdenKathy VincentXOMA Royalty CorporationKV Consulting & Management+1-646-438-9754kathy@kathyvincent.comjuliane.snowden@xoma.com

Acquisition

20 Mar 2025

·www.globenewswire.com

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about April 15, 2025, to respective holders of record at the close of business on April 3, 2025. About XOMA Royalty CorporationXOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. Investor contact:Juliane SnowdenXOMA Royalty Corporation+1-646-438-9754juliane.snowden@xoma.com Media contact:Kathy VincentKV Consulting & Management+1-310-403-8951kathy@kathyvincent.com

06 Feb 2025

·www.echemi.com

Pfizer Reports 2024 Earnings with $63.6 Billion Revenue and Concerns Over Innovation

On February 4, Pfizer announced its financial results for the fourth quarter and the entire year of 2024, revealing a total revenue of $63.6 billion, a 7% increase year-on-year. The fourth quarter alone saw revenues of $17.8 billion, reflecting a substantial 22% growth compared to the same period last year. However, the net profit for the year was $8.031 billion, with only $410 million generated in the fourth quarter, raising concerns among investors. Pfizer operates through three main business segments: Generic Medicines, Specialty Medicines, and Oncology. The Generic Medicines division reported annual revenues of $30.135 billion, a 2% decline from the previous year. In contrast, the Specialty Medicines segment achieved $16.652 billion in revenue, marking an 11% increase, while the Oncology division saw a 25% rise in revenue, totaling $15.612 billion. In the Generic Medicines segment, sales of the COVID-19 vaccine reached $5.353 billion, down 52% year-on-year. Despite this significant drop, there is no indication that the vaccine has fallen out of favor. Sales of apixaban totaled $7.366 billion, up 9%, although this product is nearing the end of its lifecycle. The pneumonia vaccine family generated $6.411 billion, a slight 1% decline. Notably, sales of Rimegepant, an oral CGRP inhibitor, surged to $1.263 billion, a 36% increase from 2022. The RSV bivalent vaccine Abrysvo brought in $755 million, down approximately $150 million from the previous year. Other pipeline products primarily consist of Pfizer's mature offerings, which generally experienced declines. In the Specialty Medicines sector, the drug Vyndaqel for transthyretin amyloidosis proved to be a significant revenue generator, contributing $5.411 billion in sales, a remarkable 64% increase. However, sales of tofacitinib fell 31% to $1.168 billion due to patent cliffs affecting the immediate-release formulation. The older drug ilaprazole saw sales of $690 million, down 17% year-on-year. Surprisingly, the antibiotic sufentanil still managed to generate $637 million in sales, despite a 4% decline, with a significant portion likely coming from China. The injectable ceftazidime-avibactam (Sivextro) achieved $586 million in sales, a 16% decline, marking it as the first cephalosporin antibiotic to surpass $500 million in sales since 2010. In the Oncology division, palbociclib generated $4.367 billion, down 8% year-on-year. Enzalutamide saw revenues of $2.039 billion, a 23% increase. The new drug padcev (enfortumab vedotin) performed exceptionally well, achieving $1.588 billion in sales during its first full fiscal year. Adcetris (brentuximab vedotin) also showed strong performance, with sales soaring to $1.089 billion. Axitinib generated $978 million, down 6%, while bosutinib remained stable at $645 million. Despite maintaining its position as the world's largest pharmaceutical company, Pfizer faces significant challenges regarding innovation and pipeline development. As of December 2024, the company's market capitalization stood at $150 billion, significantly lower than competitors such as Eli Lilly ($750 billion), Johnson & Johnson ($350 billion), AbbVie ($320 billion), Novo Nordisk ($300 billion), Merck ($250 billion), Roche ($220 billion), Novartis ($210 billion), and AstraZeneca ($200 billion). The pressure to innovate and expand its product pipeline remains a critical concern for Pfizer moving forward.

VaccineFinancial StatementDrug ApprovalClinical ResultBiosimilar

100 Deals associated with Sufentanil Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D00845	Sufentanil Citrate	N01AH03	DB00708

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Pain	United States	Vertical Pharmaceuticals LLC	02 Nov 2018
Pain	European Union	Laboratoire Aguettant SAS	25 Jun 2018
Pain	Iceland	Laboratoire Aguettant SAS	25 Jun 2018
Pain	Liechtenstein	Laboratoire Aguettant SAS	25 Jun 2018
Pain	Norway	Laboratoire Aguettant SAS	25 Jun 2018
Pain, Postoperative	European Union	FGK Representative Service GmbH	18 Sep 2015
Pain, Postoperative	Iceland	FGK Representative Service GmbH	18 Sep 2015
Pain, Postoperative	Liechtenstein	FGK Representative Service GmbH	18 Sep 2015
Pain, Postoperative	Norway	FGK Representative Service GmbH	18 Sep 2015
Anesthesia	United States	Rising Pharmaceuticals, Inc.Startup	04 May 1984
Vaginal delivery procedure	United States	Rising Pharmaceuticals, Inc.Startup	04 May 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breakthrough Pain	Phase 2	United States	Talphera, Inc.	01 Apr 2009
Analgesia	Phase 1	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	07 Mar 2025
Chronic Pain	Phase 1	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	08 Mar 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04959812 (CTgov)	Phase 1/2	Hemorrhage	46	sufentanil (Sufentanil)	waroughzab(spytxomsgx) = pyasijvagx pohrqcnjes (idhvmrxzif, 412) View more	-	11 Jul 2024
				Placebo (Placebo)	waroughzab(spytxomsgx) = kwxuweqmve pohrqcnjes (idhvmrxzif, 271) View more
NCT04561375 (CTgov)	Phase 4	-	61	Sufentanil (Intervention Group)	xdhqgtyoyu: Proportional odds ratio = 0.37 (95% CI, 0.13 - 1.07), P-Value = 0.067 View more	-	13 Dec 2023
				Fentanyl (Control Group)
NCT02989597 (MAPS, CTgov)	Phase 4	Pain, Postoperative	10	Spinal Fusion Surgery+Sufentanil+Methadone Hydrochloride+ketamine+Dexamethasone+Remifentanil (Intra-operative Methadone Hydrochloride)	chmyqfajyk(agfcezfhbo) = mtpnycuaww xzgaugkmxr (kbosaofkhy, oomuxkwfsw - jlwgpsaxjo) View more	-	25 Apr 2023
				Spinal Fusion Surgery+Sufentanil+ketamine+Dexamethasone+Remifentanil (Control)	chmyqfajyk(agfcezfhbo) = llvermklac xzgaugkmxr (kbosaofkhy, njzfxnrame - apbzlgdrty) View more
NCT04226495 (CTgov)	Phase 4	Anesthesia	65	Sufentanil Bolus (Sufentanil Bolus)	vrfrohgsfi(iqlqljzkph) = gcoqjxdkap yfpvddwikm (zdbhaiaxqo, wbtaukikdw - xfpvycmqhz) View more	-	28 Feb 2023
				Sufentanil Infusion (Sufentanil Infusion)	vrfrohgsfi(iqlqljzkph) = ijkgzgxguu yfpvddwikm (zdbhaiaxqo, cfjtxtsqqg - lgumqunilu) View more
NCT02573597 (CTgov)	Phase 4	Pregnancy \| Duration of labor \| Labor Pain	31	sufentanil+Bupivacaine (Part A Group 1)	lsbowdjdbf(xzqsreyfkq) = rxxfyjtpre vpdapfmylb (uilfznwyhd, 0.008) View more	-	18 Oct 2022
				sufentanil+Bupivacaine (Part A Group 2)	lsbowdjdbf(xzqsreyfkq) = mchhfyhptt vpdapfmylb (uilfznwyhd, 0.007) View more
NCT04177862 (CTgov)	Phase 4	Anesthesia \| Acute Pain	75	Sublingual Sufentanil (Sublingual Sufentanil)	bojijfqwtd(ulwnsryroh) = uvlfvzndtv iqqtlfafej (sfzhmklfbj, oaghmxutjf - vfxuebxnbi) View more	-	02 Feb 2021
				IV Fentanyl (IV Fentanyl)	bojijfqwtd(ulwnsryroh) = szrmqixbfd iqqtlfafej (sfzhmklfbj, vcincmqzgv - wzugoljpks) View more
NCT04448457 (Pubmed \| J Exp Orthop)	Not Applicable	Pain, Postoperative	72	Sufentanil sublingual tablet system (SSTS) 15 mcg	hgqembdowq(hxgyhtbvaz) = iskdbcqode hvrlhsflap (nzbmebzosn )	-	01 Jan 2020
				Oral oxycodone extended release 10mg twice daily and oral oxycodone immediate-release 5mg up to four times daily on demand	hgqembdowq(hxgyhtbvaz) = rdshppeqvv hvrlhsflap (nzbmebzosn )
NCT02662764 (CTgov)	Phase 3	Acute Pain	320	Zalviso™ 15 mcg	xphqawvhop = fzngmgiqmw fhhuyxbaqb (lalunqosra, wntjkqwyik - tatrjoquga) View more	-	08 Aug 2018
NCT01012999 (CTgov)	Phase 1/2	Pain \| Limb injury	16	sufentanil	umfatwqbfl(lwbogvuwwr) = xjpzqoteaw qcyhgagdfq (fxtyzibfss, 2.2) View more	-	22 Jun 2017
NCT02430090 (CTgov)	Phase 2	Anesthesia	45	Levobupivacaine (Levobupivacaine)	rrqriqyjnc = beewoqpbyh borekzvprb (qbrybpbtjh, mthjmeagdo - qgtpdcrqep) View more	-	10 Jun 2015
				Fentanyl+Levobupivacaine (Levobupivacaine + Fentanyl)	rrqriqyjnc = xlzczsyura borekzvprb (qbrybpbtjh, ckswaopaih - crxutiwhhp) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sufentanil Citrate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation